Home > Insider Trading > Filing (0001209191-21-070996)

Filing Details

Accession Number:: 0001209191-21-070996
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-12-22 20:01:53
Reporting Period:: 2021-12-02

Accepted Time:: 2021-12-22 20:01:53
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1808865	Iteos Therapeutics Inc.	ITOS	Biological Products, (No Disgnostic Substances) (2836)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1816196	Michel Detheux	139 Main Street Cambridge MA 02142	Chief Executive Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-12-20	9,111	$4.30	87,311	No	4	M	Direct
Common Stock	Disposition	2021-12-20	9,111	$43.94	78,200	No	4	S	Direct
Common Stock	Acquisiton	2021-12-21	19,226	$4.30	97,426	No	4	M	Direct
Common Stock	Disposition	2021-12-21	13,646	$44.15	83,780	No	4	S	Direct
Common Stock	Disposition	2021-12-21	5,580	$45.06	78,200	No	4	S	Direct
Common Stock	Acquisiton	2021-12-22	1,663	$4.30	79,863	No	4	M	Direct
Common Stock	Disposition	2021-12-22	1,514	$44.31	78,349	No	4	S	Direct
Common Stock	Disposition	2021-12-22	149	$44.92	78,200	No	4	S	Direct
Common Stock	Disposition	2021-12-22	5,007	$44.62	73,193	No	4	S	Direct
Common Stock	Disposition	2021-12-22	9,493	$45.37	63,700	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2021-12-02	313,442	$0.00	403,442	$4.30
Common Stock	Stock Option (Right to Buy)	Acquisiton	2021-12-02	313,442	$0.00	313,442	$4.30
Common Stock	Stock Option (Right to Buy)	Disposition	2021-12-02	185,000	$0.00	340,964	$4.23
Common Stock	Stock Option (Right to Buy)	Acquisiton	2021-12-02	185,000	$0.00	185,000	$4.23
Common Stock	Stock Option (Right to Buy)	Disposition	2021-12-02	52,700	$0.00	70,244	$6.15
Common Stock	Stock Option (Right to Buy)	Acquisiton	2021-12-02	52,700	$0.00	52,700	$6.15
Common Stock	Stock Option (Right to Buy)	Disposition	2021-12-02	776,600	$0.00	1,035,424	$19.00
Common Stock	Stock Option (Right to Buy)	Acquisiton	2021-12-02	776,600	$0.00	776,600	$19.00
Common Stock	Stock Option (Right to Buy)	Disposition	2021-12-02	106,200	$0.00	144,000	$41.58
Common Stock	Stock Option (Right to Buy)	Acquisiton	2021-12-02	106,200	$0.00	106,200	$41.58
Common Stock	Stock Option (Right to Buy)	Disposition	2021-12-20	9,111	$0.00	9,111	$4.30
Common Stock	Stock Option (Right to Buy)	Disposition	2021-12-21	19,226	$0.00	19,226	$4.30
Common Stock	Stock Option (Right to Buy)	Disposition	2021-12-22	1,663	$0.00	1,663	$4.30

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
90,000	2025-06-11	No	5	G	Direct
313,442	2025-06-11	No	5	G	Indirect
155,964	2030-05-01	No	5	G	Direct
185,000	2030-05-01	No	5	G	Indirect
17,544	2030-06-18	No	5	G	Direct
52,700	2030-06-18	No	5	G	Indirect
258,824	2030-07-23	No	5	G	Direct
776,600	2030-07-23	No	5	G	Indirect
37,800	2031-03-01	No	5	G	Direct
106,200	2031-03-01	No	5	G	Indirect
80,889	2025-06-11	No	4	M	Direct
61,663	2025-06-11	No	4	M	Direct
60,000	2025-06-11	No	4	M	Direct

Footnotes

The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.8 to $44.2, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.8 to $44.79, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.825 to $45.29, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.85 to $44.73, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.12 to $45.11, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.15 to $45.83, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The reporting person transferred these stock options to MG3A, a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager.
One-fourth of the shares subject to the stock option vested on January 1, 2019. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date.
One-fourth of the shares subject to the stock option vested on May 1, 2021. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date.
One-fourth of the shares subject to the stock option vested on June 1, 2021. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date.
One-fourth of the shares subject to the stock option vested on July 23, 2021. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date.
One-fourth of the shares subject to the stock option will vest on March 1, 2022, subject to the reporting person's continuous service relationship with the Issuer. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date.